

Board of Directors: 11.1.18

Agenda Item: Bo.1.18.25

## Report from the Major Projects Committee 20 December 2017

<b>Presented by:</b>	Amjad Pervez, Non-Executive Director	<b>Author:</b>	Fiona Ritchie, Trust Secretary
<b>Previously considered by:</b>	n/a		

<b>Key points</b>	<b>Purpose:</b>
1. This paper provides a brief summary of the key matters that were discussed at the meeting of the Major Projects Committee which was held on 20 December 2017.	To discuss and note

<b>Executive Summary:</b>
The purpose of the Major Projects Committee, as set out in its Terms of Reference, is to provide detailed scrutiny of the Foundation Trust's major projects in order to provide assurance and, if necessary, raise concerns or make recommendations to the Board of Directors.

<b>Financial implications:</b>
--------------------------------

<b>Regulatory relevance:</b>
------------------------------

<b>Monitor:</b>	
-----------------	--

<b>Equality Impact / Implications:</b>	<b>Is there likely to be any impact on any of the protected characteristics?</b> (Age, Disability, Gender, Gender Reassignment, Pregnancy and Maternity, Race, Religion or Belief, Sexual Orientation, Health Inequalities, Human Rights) Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> If yes, what is the mitigation against this?
--	--

<b>Other:</b>	
---------------	--

<b>Strategic Objective:</b>	To deliver our financial plan and key performance targets
<i>Reference to Strategic Objective(s) this paper relates to</i>	To provide outstanding care for patients
	To be a continually learning organisation

### Major Projects Committee – 20 December 2017

#### 1. Introduction

The purpose of this paper is to advise the Board of Directors of the key matters discussed and a brief summary of agenda items of the Committee which was held on 20 December 2017.

**Board of Directors: 11.1.18**

**Agenda Item: Bo.1.18.25**

---

## **2. Key Matters discussed at the meeting held on 20 December 2017**

- Special Purpose Vehicle
- EPR
- Wolfson Centre for Applied Health Research

## **3. Agenda items**

### **3.1 Special Purpose Vehicle**

This item had presentations from the WYAAT E&F Project Team. There is still further work to be progressed with a latest version of the draft business case to be discussed at January Board of Directors meeting.

### **3.2 EPR Update**

The EPR continues to function predominantly well across the Trust. The production of metrics is in progress so that adoption and usage can be monitored routinely.

The work on regulatory reporting is almost complete. Completed work includes the interface to the regional cancer information system (PPM) to produce the cancer report and DM01 for diagnostics bar one specialty. The RTT remaining issues are now being assessed from a data quality perspective to both reconcile the report and to then identify any remaining technical issues.

Issues on EPR and integration with other FT IT systems were discussed.

The EPR continues to be embedded in the Trust in what is expected to be a 6 month long process. There are some out-patient clinics where the pre go-live volume has not returned. The operational teams are working through ways and means to bring the volume back up in these clinics.

The work to ensure benefits are being realised has begun with an initial review on alignment to existing work expected to be completed in December 2017.

### **3.3 Pathology Joint Venture Update**

An update was given on the Pathology Joint Venture and how it links in with the proposed NHSI pathology network.

### **3.4 Wolfson Centre for Applied Health Research**

A report was presented that updated the Committee on the progress made with respect to the development of the Wolfson Centre for Applied Health Research.

### **3.5 Private Patients**

The Director of Strategy & Integration advised the Committee that he was beginning some work looking at where Private Patients fits into the existing strategies of BTHFT.

## **4. Escalation to the Corporate Risk Register**

**Board of Directors: 11.1.18**

**Agenda Item: Bo.1.18.25**

---

There were no items to escalate to the Corporate Risk Register.

**5. Recommendation**

The Board of Directors is asked to note the above points.